FDA, FTC Crack Down on Unapproved, Illegally Marketed Opioid Cessation Products
January 24th 2018Officials with the FDA and the Federal Trade Commission (FTC) today issued joint warnings to companies selling unapproved opioid cessation products with deceptive claims about their ability to treat opioid addiction and withdrawal.
Read More
New Compounding Pharmacy Policy Priorities Plan Released
January 23rd 2018Officials with the FDA have issued 2 final guidance documents to help implement the 2018 Compounding Policy Priorities Plan, which explain the agency’s policies on the “essentially a copy” provisions of sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Read More